Live Breaking News & Updates on Brian lamoreaux

Stay updated with breaking news from Brian lamoreaux. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Brian LaMoreaux, MD: Outcomes Following Discontinuation of Pegloticase Treatment

After a 12-week gap, 5% of patients returned to pegloticase and responded well.

California , United-states , San-diego , Brian-lamoreaux , American-college-of-rheumatology , Horizon-therapeutics , Outcomes-following-discontinuation , Pegloticase-therapy , American-college , Rheumatology-information-system ,

Brian LaMoreaux, MD: Use and Efficacy Post-Pegloticase Treatment

The most successful outcomes were observed in patients with at least 6 months of pegloticase therapy who promptly began oral therapy within 60 days.

San-diego , California , United-states , Brian-lamoreaux , American-college-of-rheumatology , Rheumatology-network-database , Horizon-therapeutics , Urate-lowering-therapy-use , Efficacy-following-pegloticase-treatment , American-college ,

Horizon Therapeutics plc: Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology

Horizon Therapeutics plc: Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , Ireland , Tina-ventura , Eimear-rigby , Brian-lamoreaux , Erin-linnihan , Amanda-phraner , Clin-rheumatol , Facebook , Patients-with-uncontrolled-gout-co , Exchange-commission , Twitter

Horizon Therapeutics (HZNP) Reports Publication of Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA

Horizon Therapeutics (HZNP) Reports Publication of Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Ireland , Tina-ventura , Amanda-phraner , Erin-linnihan , Clin-rheumatol , Brian-lamoreaux , Facebook , Patients-with-uncontrolled-gout-co , Exchange-commission , Twitter , Nasdaq

Study Demonstrates Increased Benefits of Pegloticase and Methotrexate Cotherapy for Uncontrolled Gout

At month 12, response rate was significantly higher in patients receiving pegloticase and methotrexate when compared with concomitant placebo.

Brian-lamoreaux , University-of-alabama-at-birmingham-kenneth-saag , University-of-alabama-at-birmingham , Kenneth-saag , Clinical-immunology ,

Long COVID and Patients with Rheumatic Disease: Perspective from EULAR 2023

A group of rheumatologists attending EULAR 2023 provide perspective on their concern regarding the potential threat posed by long COVID in patients with rheumatic disease.

Netherlands , Holland , George-karpouzas , Brian-lamoreaux , Lars-erik-kristensen , R-george-karpouzas , Cozianna-ciurtin , Coziana-ciurtin , University-college-london , Global-rheumatology-alliance-vaccine , Parker-institute , Division-of-rheumatology-at

Pegloticase Use Could Contribute to Bone Remodeling in Gout Patients

An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.

Milan , Lombardia , Italy , Brian-lamoreaux , European-congress , Horizon-therapeutics ,

Study Shows Pegloticase Plus Methotrexate Improves Quality of Life in Gout Patients

An analysis of patient-reported outcomes data from the MIRROR trial offers insight into the effects of pegloticase plus methotrexate on quality of life and various disease activity indices.

Brian-lamoreaux , Health-assessment-questionnaire , European-congress , Horizon-therapeutics , Biologics-license-application ,

Pegloticase Use and Quality of Life in Uncontrolled Gout, with Brian LaMoreaux, MD

Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.

Alaska , United-states , Brian-lamoreaux , John-botson , Health-assessment-questionnaire , European-congress , Drug-administration , Orthopedic-physicians-alaska , Biologics-license-application , Physician-global-assessment , Horizon-therapeutics ,

Horizon Therapeutics plc: New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology

-- New data illustrate impact of KRYSTEXXA (pegloticase) injection with methotrexate to improve patient outcomes and clinical measures for uncontrolled gout -- Horizon Therapeutics plc (Nasdaq: HZNP)

Milan , Lombardia , Italy , United-states , Ireland , Brian-lamoreaux , Amanda-phraner , Erin-linnihan , Tina-ventura , Facebook , European-congress , Linkedin